Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Serum thymidine kinase--a marker of bone marrow toxicity during treatment with zidovudine.

Research output: Contribution to journalJournal articleResearch

  1. Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prevalence and risk factors of prolonged QT interval and electrocardiographic abnormalities in persons living with HIV

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

    Research output: Contribution to journalJournal articleResearchpeer-review

  • C Pedersen
  • S Ingeberg
  • L S Teglbjaerg
View graph of relations
Serum thymidine kinase (S-TK) was measured weekly in 16 randomly selected patients with AIDS or AIDS-related complex (ARC; Centers for Disease Control group IV A or group IV C-2) who participated in a controlled study of the efficacy of zidovudine therapy. S-TK increased significantly (P less than 0.01) in the zidovudine group, whereas it remained stable in the placebo (control) group. On the basis of this observation, the value of S-TK measurements as a predictor of bone marrow toxicity during zidovudine therapy was investigated in 42 patients with AIDS or ARC who received zidovudine as part of their usual treatment. There was a significant association between S-TK, haemoglobin and neutrophil counts measured after the first 4 weeks of therapy and the risk of developing bone marrow toxicity during the following 6 months. Combined, measurements of S-TK and neutrophil counts seem to be well suited for the identification of patients who have a high probability for developing bone marrow toxicity during zidovudine treatment.
Translated title of the contributionSerum thymidine kinase--a marker of bone marrow toxicity during treatment with zidovudine.
Original languageEnglish
JournalAIDS (London, England)
Volume3
Issue number11
Pages (from-to)743-746
Number of pages4
ISSN0269-9370
Publication statusPublished - 1989

ID: 32503035